Yousaf Dawood

Dr. Yousaf Dawood

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

18 October 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Atheer ZgairAtheer Zgair
Atheer Zgair
YDYousaf Dawood
Yousaf Dawood
SISuhaib Ibrahem
Suhaib Ibrahem
HBHyun-Moon Back
Hyun-Moon Back
LKLeonid Kagan
Leonid Kagan
Jong Bong LeeJong Bong Lee
Jong Bong Lee
The bioavailability of orally administered drugs could be impacted by intestinal and hepatic first-pass metabolism. Testosterone undecanoate (TU), an orally administered ester prodrug of testosterone, is significantly subjected to first-pass metabolism. However, the individual contribution of intestinal and hepatic first-pass metabolism is not well determined. Therefore, the aim of the current study was to predict the metabolic contribution of each site. The hydrolysis–time profiles of TU incubation in human liver microsomes and Caco-2 cell homogenate were used to predict hepatic and intestinal first-pass metabolism, respectively. The in vitro half-life (t1/2 inv) for the hydrolysis of TU in microsomal mixtures was 28.31 ± 3.51 min. By applying the “well-stirred” model, the fraction of TU that could escape hepatic first-pass metabolism (FH) was predicted as 0.915 ± 0.009. The incubation of TU in Caco-2 cell homogenate yielded t1/2 inv of 109.28 ± 21.42 min, which was applied in a “Q gut” model to estimate the fraction of TU that would escape intestinal first-pass metabolism (FG) as 0.114 ± 0.02. Accordingly, only 11% of the absorbed fraction of TU could escape intestinal metabolism, while 91% can pass through hepatic metabolism. Hence, compared to the liver, the intestinal wall is the main site where TU is significantly metabolised during first-pass effect.

2 December 2025 in Molecules
Verified
Journal Article
Open access
PDF file
YDYousaf Dawood
Yousaf Dawood
Atheer ZgairAtheer Zgair
Atheer Zgair
MYMun Fei Yam
Mun Fei Yam
NANur Hidayah Kaz Abdul Aziz
Nur Hidayah Kaz Abdul Aziz
Background/Objectives: Aldose reductase (AR) plays a crucial role in the accumulation of oxidative factors that lead to oxidative stress-related neuroinflammation. This study aims to find a novel agent from natural sources that can inhibit AR. Methods: Different extracts of Orthosiphon stamineus Benth (OS) leaves and its active constituents, eupatorin (EUP), rosmarinic acid (RA), sinensetin (SEN) and 3-hydroxy-5,6,7,4-tetramethoxyflavone (TMF), were used to identify the potential inhibition effect of AR. A new high-performance liquid chromatography (HPLC) method was developed to determine these phytochemicals using the Shimadzu LC-20AD HPLC system. In addition, the in vitro inhibition effect of OS ethanol extracts (95% and 50%) and OS components EUP, RA, and SEN was investigated in recombinant AR (AKR1B1). Results: In this study, the developed HPLC method was precise and accurate, and demonstrated clear separation of the four compounds—EUP, RA, SEN, and TMF—in the ethanolic extract. The contents of the four selected compounds—EUP, RA, SEN, and TMF—in 95% ethanolic extract were 2.35, 11.91, 0.94, and 0.18%, respectively. RA showed the highest concentration among the selected compounds, indicating that RA is the major constituent of this plant. The in vitro assay showed significant inhibition of the AR enzyme by RA and OS ethanol extracts 95% and 50% (IC50: 41.42 µM; 63.42 µg/mL and 93.22 µg/mL, respectively). Conclusions: The ethanolic extract of OS and RA could be a promising therapeutics option for the treatment of oxidative stress-related neuroinflammation disorders by inhibiting AR.

5 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Atheer ZgairAtheer Zgair
Atheer Zgair
YDYousaf Dawood
Yousaf Dawood
SISuhaib Ibrahem
Suhaib Ibrahem
Jong Bong LeeJong Bong Lee
Jong Bong Lee
WFWanshan Feng
Wanshan Feng
PGPavel Gershkovich
Pavel Gershkovich
Male hypogonadism is often treated by testosterone (T) replacement therapy such as oral administration of the ester prodrug, testosterone undecanoate (TU). However, the systemic exposure to T following oral TU is very low due to esterase-mediated metabolism, particularly in the small intestine. The aim of this work was to examine the esterase-inhibitory effect of natural fruit extract of strawberry (STW) on the intestinal degradation of TU as a potential approach to increasing the oral bioavailability of T. Herein, the hydrolysis of TU was assessed in fasted state simulated intestinal fluid with added esterase activity (FaSSIF/ES) and Caco-2 cell homogenates in the presence of STW extract. It is noteworthy that STW substantially inhibited the degradation of TU in FaSSIF/ES and Caco-2 cell homogenates at concentrations that could be achieved following oral consumption of less than one serving of STW fruit. This can significantly increase the fraction of unhydrolyzed TU in the intestinal lumen as well as in enterocytes. In addition, it was demonstrated that TU has high intestinal lymphatic transport potential as the association of TU with plasma-derived human chylomicrons was in the range of 84%. Therefore, oral co-administration of TU with STW could potentially increase the intestinal stability of TU and consequently the contribution of lymphatically delivered TU to the systemic exposure of T in vivo.

19 August 2026 in Molecules
Verified
Journal Article
Open access
PDF file
YDYousaf Dawood
Yousaf Dawood
Atheer ZgairAtheer Zgair
Atheer Zgair
MYMun Fei Yam
Mun Fei Yam
NANur Hidayah Kaz Abdul Aziz
Nur Hidayah Kaz Abdul Aziz
Background: Traditional antidepressants are associated with undesirable side effects, limited efficacy, and delayed therapeutic responses. Natural products have emerged as a potential alternative to these drugs. This research aimed to investigate the antidepressant-like activity and possible mechanism of Orthosiphon stamineus (OS) leaf ethanolic extract. Methods: Molecular docking and in vitro studies were performed to assess the inhibitory activity of ethanolic extracts of OS leaves against the monoamine oxidase (MAO-A) enzyme. Behavioral tests were used to evaluate the antidepressant-like activity of the 95% ethanol extract in reserpine-treated rats, followed by histopathological examination and measurement of hippocampal serotonin (5-HT), norepinephrine (NE), and brain-derived neurotrophic factor (BDNF). Results: The main active compounds, particularly rosmarinic acid and eupatorin, exhibited favorable binding affinities to the MAO-A active site. The 95% and 50% ethanol extracts of OS showed dose-dependent MAO-A inhibitory activity with ICs50 of 88.67 and 103.2 µg/mL, respectively. The 95% ethanol extract of OS leaves showed a significant reduction in immobility time, restored locomotor activity, and preserved hippocampal morphology. Notably, the higher dose of OS extract (150 mg/kg) significantly enhanced hippocampal expression of 5-HT and NE, with a moderate upregulation of BDNF. Conclusions: These findings suggest that the 95% ethanol extract of OS leaves exhibits promising antidepressant-like effects, which may be mediated through monoamine modulation and BDNF expression and partially through MAO-A enzyme inhibition.

1 January 2024 in Qatar Medical Journal
Verified
Journal Article
Open access
YDYousaf Dawood
Yousaf Dawood
SASaddam M. Abed
Saddam M. Abed
YKYousif H. Khalaf
Yousif H. Khalaf
Objectives: The aim of this study was to investigate the potential cardiac side effects associated with Pfizer/BioNTech and Sinopharm vaccines. Methods: A total of 200 healthy volunteers were enrolled after receiving two doses of Pfizer/BioNTech or Sinopharm vaccine 21 days apart. In addition, 100 healthy, unvaccinated individuals were included as a control group. Cardiac biomarkers such as cardiac troponin-I (cTnI), creatinine kinase–myocardial band (CK-MB), and myoglobin (MYO) were measured 4 days after receiving the second dose of vaccine. In addition, the SARS-CoV-2 neutralizing antibody levels of all participants were also determined. Results: Post-vaccination findings in both vaccinated groups were comparable. There was no statistically significant difference in cTnI, MYO, and CK-MB levels between the Pfizer/BioNTech and Sinopharm vaccine groups. Furthermore, our results showed that the levels of SARS-CoV-2 neutralizing antibodies stimulated by the Pfizer–BioNTech vaccine were significantly higher (171.19, p < 0.001) compared to the Sinopharm vaccine (70.14). Owing to the successful efficacy of the vaccine and based on the available data, COVID-19 vaccines remain the best option to eliminate the pandemic and its complications. Conclusion: Our study shows that both Pfizer–BioNTech and Sinopharm vaccines are safe for the heart in the short term, with no significant changes in cardiac biomarkers observed four days after vaccination. The findings suggest that these vaccines are effective and do not pose an immediate risk to cardiovascular health within the observed time frame. However, further research is required to assess the long-term cardiac safety profiles of these vaccines.